anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
3D printed scaffolds have revolutionized the field of regenerative medicine by overcoming the lacunas such as precision, customization, and reproducibility observed through traditional methods of scaffold preparation such as freeze-drying, electrospinning, etc. Combining the advantages of 3D printed scaffolds along with bioactive cues such as signaling molecules can be an effective treatment approach. In the present study, cellulose nanocrystals (CNCs) along with gelatin, in different ratios, were used for scaffold preparation through the direct ink writing technique and thoroughly characterized. The scaffolds showed porous microstructure, high swelling ratio (∼390 to 590), degradability and porosity (∼65 %). In vitro biocompatibility assays showed high biocompatibility and no toxicity through live-dead, proliferation and hemolysis assay. Further, the optimum formulation was functionalized with nitric oxide (NO)-releasing modified gelatin to enhance the scaffold's biomedical applicability. Functionality assays with this formulation, scratch, and neurite outgrowth showed positive effects of NO on cell migration and neurite length. The study presents the fabrication, modification, and biomedical applicability of the aforementioned inks, which paves new pathways in the field of 3D printing of scaffolds with significant potential for biomedical applications, soft tissue engineering, and wound dressing, for example.
PURPOSE: A process of preparing the titled prophylactic and therapeutic composition containing an alcohol extract of mixtures of Schizandra Fructus, Rehmanniae Radix, Ginseng Radix, Lycii Fructus, Cornus officinalis and Corni Fructus Poria cocos as a main component is provided. Whereby, the composition is useful as an agent for stimulating hematopoiesis as well as prophylaxis or treatment of male reproductive function. CONSTITUTION: A mixture of Schizandra chinensis Baill., Cistanche deserticola Y.C. Ma, Cuscuta japonica Choisy., Eucommia ulmoides Oliver, Morinda officinalis How, Rehmanniae glutinosa Liboschitz, Panax schinseng Nees, Lycium chinense Mill., Dioscorea batatas Decne., Cornus officinalis Sieb. et Zucc., Angelica sinensis (Oliv.) Diels, Astragalus membranaceus Bunge, Poria cocos (Fr.) Wolf, Polygala tenuifolia Willd., Atractylodes macrocephala Koidz., Thuja orientalis L., Achyranthes bidentata Bl., Alisma canaliculatum A. Br. et Bouche, Cinnamomum loureirii Nees and Torilis japonica (Houtt.) DC. in a ratio of 6:3:3:3:3:3:2:2:2:2:2:2:1.5:1.5:1.5:1:1:1:1. is extracted in water at 80 to 90deg.C for 2 to 3hr 3 times or more.
A comparator cohort which includes participants exposed to oral azithromycin (AZ) with a qualifying indication of uncomplicated acute sinusitis or bronchitis and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
The application relates to the field of medicines, in particular to application of gamboge cola or GB1 in preparing a medicine for up-regulating PPAR alpha expression. Application of GB1 in preparing medicine for up-regulating PPAR alpha expression is provided. The inventors have detected by immunoblotting and fluorescence quantitative PCR, and have shown that GB1 can promote the expression of PPAR alpha. Results of immunoblotting and real-time fluorescent quantitative PCR showed successful PPAR α silencing by siRNA. After PPAR alpha is silenced by siRNA, the pharmacological activity of GB1 on HepG2 cells is disappeared, and the silencing of PPAR alpha eliminates the improvement effect of GB1 on the lipid accumulation and oxidative stress in HepG2 cells. Thus, GB1 was used in a medicament which successfully upregulated PPAR α expression.
Grid cells in the entorhinal cortex (EC) encode an individual's location in space, integrating both environmental and multisensory bodily cues. Notably, body-derived signals are also primary signals for the sense of self. While studies have demonstrated that continuous application of visuo-tactile bodily stimuli can induce perceptual shifts in self-location, it remains unexplored whether these illusory changes suffice to trigger grid cell-like representation (GCLR) within the EC, and how this compares to GCLR during conventional virtual navigation. To address this, we systematically induced illusory drifts in self-location toward controlled directions using visuo-tactile bodily stimulation, while maintaining the subjects' visual viewpoint fixed (absent conventional virtual navigation). Subsequently, we evaluated the corresponding GCLR in the EC through functional MRI analysis. Our results reveal that illusory changes in perceived self-location (independent of changes in environmental navigation cues) can indeed evoke entorhinal GCLR, correlating in strength with the magnitude of perceived self-location, and characterized by similar grid orientation as during conventional virtual navigation in the same virtual room. These data demonstrate that the same grid-like representation is recruited when navigating based on environmental, mainly visual cues, or when experiencing illusory forward drifts in self-location, driven by perceptual multisensory bodily cues.
Investigators will conduct a within-subject pilot study of 6 tutors and 6 children to answer research questions about V-Motive's ability to perform its intended function. The goal is to evaluate the feasibility, usability, and the potential of V-Motive to deliver comprehensive, individualized video modeling that is integrated with a child's program. Investigators will also use descriptive statistics to provide preliminary insight into the potential impact of the system on a child's performance in their ABA therapy. However, these data are NOT intended to show cause or to show effectiveness. The study will answer the following questions: 1) 3) Can V-Motive be feasibly used during ABA therapy to positively impact a child's performance within 4 weeks? 2) How laborious is it to construct a fully-indexed video repository from therapy footage using V-Motive? 3) How accurate is the system in suggesting and cueing up appropriate video for playback on demand?
PURPOSE: A composition containing alpha-lipoic acid for preventing or treating alopecia is provided to suppress DKK-1 expression by DHT. CONSTITUTION: A pharmaceutical composition for preventing or treating alopecia contains alpha-lipoic acid as an active ingredient. The alopecia is male alopecia. A cosmetic composition for preventing or treating alopecia contains alpha-lipoic acid as an active ingredient. A health food composition for preventing or treating alopecia contains alpha-lipoic acid as an active ingredient. A kit for treating or preventing alopecia contains an additional activating agent of minoxidil, anti-androgen, 5 alpha-reductase inhibitor, aromatase inhibitor, or corticosteroid and alpha-lipoic acid.
The invention provides a method for efficiently and synchronously extracting flavone, alkaloid and phenol from lotus leaves by a water medium method. The method comprises the steps of lotus leaf powdering, lotus leaf powder enzymolysis, ultrasonic-assisted surfactant extraction, filtration, concentration and the like. The water medium method adopts glycerol and Tween 80 as medium for extraction, can efficiently extract alkaloid and quercetin in folium Nelumbinis, and glycerol has great advantages in extracting flavone and phenols. The method solves the problems that the prior multi-purpose organic solvent extraction for industrial extraction easily causes organic matter residue and is difficult to extract the quercetin, and simultaneously optimizes parameters such as enzyme preparation selection, enzymolysis pH value, ultrasonic conditions and the like. And the prepared extract has good stability. The lotus leaf extract prepared by the method is not suitable for any organic reagent in the extraction process, strictly complies with the regulation requirements, can be directly applied to beverages and other foods, and has the characteristics of greenness, safety, economy, high efficiency and the like.
This will be the EXOPULSE Mollii Suit Active Stimulation. Stimulation will go on for 60 minutes while control unit is on for 60 minutes.
Will receive standard dose Lift mobile mindfulness program intervention content, app-based response to elevated symptoms, and no introductory call from a therapist. This program lasts 1 month and includes 4 unique weeks' worth of audio, video, and text content.
Most cancer cells that do not respond to a single immune checkpoint inhibitor escape through the innate immune escape mechanism, allowing them to grow and survive. Different from the inherent resistance mechanism, some patients who initially responded to immune checkpoint inhibitors developed disease progression after a period of treatment and follow-up, suggesting acquired resistance. Therefore, clinical strategies continue to be applied to overcome inherent and acquired resistance to improve the clinical efficacy of immune checkpoint inhibitors. Combining an immune checkpoint inhibitor with another drug that has both immune regulation and anti-tumor properties can enhance the anti-tumor efficacy of any one drug when used alone. Studies have shown that tumor angiogenesis participates in anti-tumor immune regulation and will aggravate the tumor immunosuppressive microenvironment, and anti-angiogenesis therapy can normalize the abnormal vascular structure and function of tumors, and help the recruitment and infiltration of effector T cells. , Reduce the accumulation of immunosuppressive regulatory T cells, relieve the immunosuppressive state, thereby improving the efficacy of immunotherapy. The combination of anti-angiogenic drugs and immune checkpoint inhibitors has become a promising treatment strategy.
Adult Patients

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data derived from Velphoro clinical trials reflect exposure to Velphoro in 2 active-controlled clinical studies involving a total of 778 adult patients on hemodialysis and 57 adult patients on peritoneal dialysis exposed for up to 55 weeks. Dosage regimens ranged from 250 mg to 3,000 mg per day.

In a parallel design, dose-finding study of Velphoro with a treatment duration of 6 weeks in hemodialysis patients, adverse reactions for Velphoro (N=128) were similar to those reported for the active-control group (sevelamer hydrochloride) (N=26), with the exception of discolored feces (12%) which did not occur in the active-control group. Diarrhea was reported in 6% of patients treated with Velphoro. In a 55-week, open-label, active-controlled, parallel design, safety and efficacy study involving 968 hemodialysis patients and 86 peritoneal dialysis patients treated with either Velphoro (N=707 including 57 peritoneal dialysis patients) or the active-control (sevelamer carbonate) (N=348 including 29 peritoneal dialysis patients), adverse reactions occurring in more than 5% in the Velphoro group were diarrhea (24%), discolored feces (16%), and nausea (10%). The majority of diarrhea events in the Velphoro group were mild and transient, occurring soon after initiation of treatment, and resolving with continued treatment. Adverse reactions occurred at similar rates in hemodialysis and peritoneal dialysis patients. The most common adverse reactions (>1%) leading to withdrawal were diarrhea (4%), product taste abnormal (2%), and nausea (2%).

Pediatric Patients

In an open-label, randomized study, with a 10-week dose titration period and 24-week safety extension, 60 patients 6 to 18 years of age received at least one dose of Velphoro, including 30 patients (50%) exposed for at least 19 weeks [see Clinical Studies ( 14.3)] . The safety profile of Velphoro in pediatric patients was similar to that observed in adult patients. Velphoro is not approved in pediatric patients 6 years to less than 9 years of age because of the lack of an appropriate dosage strength.
Immunological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA  for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.
PROBLEM TO BE SOLVED: To obtain a nucleic acid-containing complex characterized by a nucleic acid and a biodegradable polymer, especially a positively charged, water- insoluble and biodegradable polymer included therein. SOLUTION: This nucleic acid-containing complex can feed a required nucleic acid, especially DNA to a site requiring the treatment sustainedly for a long time by the excellent nucleic acid releasability thereof. The complex can be taken in by a phagocyte such as a macrophage and target site-specifically delivered to enable the nucleic acid to target site-specifically exhibit the function of the nucleic acid, and to enable more specific gene therapy. The complex does not provide side effects such as the generation of recombinant, and toxicity unlike the use of a virus vector such as adenovirus, and a ribosome. As a result, the nucleic acid-containing complex is especially suitable for the use in the field of the gene therapy.  The low dose of the gene to be administered in the gene therapy is achieved because the complex can enhance the biological activities of the introduced nucleic acid.
The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4 +  T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified extracellular domains of ligands. The invention also provides humanized and human antibodies to the ligand. The invention further provides methods of using the ligand and the antibodies in treatment of diseases and conditions of the immune system. The invention also provides methods of monitoring activated CD4 +  T-cells using the ligands or fragments thereof.
Three hundred patients with ischemic stroke (18-65 years) will be enrolled for the validation of the Czech version of the the Stroke Impact Scale 3.0. The reliability and validity study will have a cross-sectional design.
A process for preparation of perindopril of formula (II) and salts thereof which is simple, safe, convenient and cost-effective. The process involves reaction of compound of formula (I), wherein X is chlorine or bromine with compound of formula (VII) wherein A signifies that the six-membered ring of the bicyclic system is either saturated or unsaturated to give compound of formula (VIII), wherein A is as defined above, followed by catalytic hydrogenation of the compound of formula (VIII) thus obtained to give the perindopril of formula (II). The above process for the manufacture of perindopril would specifically avoid the use of harmful chemicals like phosgene or costly coupling agents like dicyclohexylcarbodiimide and 1-hydroxybenxotriazole usually used for such manufacture. The process would also not require any intervention of a catalyst and does not require any alkaline or acidic reaction conditions. Importantly, the process provides for manufacture of perindopril with high stereoselectively giving perindopril (II) having (S)-configuration in all the five chiral centres of the molecule, conforming to pharmacoepeial specifications. The invention also relates to a method for preparation of the compound of formula (I) and also to a method for preparation of N-[(S)-1-carbethoxybutyl]-(S)-alanine of formula (III) used in the process.
GM-CSF, sargramostim 150 μg/m\^2 subcutaneous injection daily for 28 days in a 28-day cycle until disease progression or unacceptable toxicity fora median of 3 cycles. GM-CSF, sargramostim dose escalation was permitted up to 250 μg/m\^2 per day if applicable based on toxicity and white blood cell count.
PURPOSE: To obtain a medicine containing teprenone as an active ingredient, effective for increasing a mucin layer on the surface of an eye, and especially useful for preventing, treating and improving dry eyes, eye strain, etc. CONSTITUTION: This agent for treating dry eye contains 0.1-10wt.% of teprenone of the formula (chemical name: 6,10,14,18-tetramethyl-5,9,13,17-nonadecatetraen-2- one) as an active ingredient. A surfactant, an isotonic agent, a pH-controlling agent, an antiseptic, an antifungal agent, an antioxidizing agent, etc., may further be added, and is prepared into an eye drop. The teprenone has a pharmacological action to increase mucin layer which is in contact with the surface of a corneal conjunctiva. The corneal conjectiva layer is covered with tear, and has a three layer structure comprising an oil layer, a liquid layer and a mucin layer from the outermost surface. The dry eye-treating agent can alleviate syndromes such as eye strain, foreign touch, dry touch, unpleasantness, dimness, itching, pain, accommodation failure, eye mucus, and excessive tear.
Disclosed herein is a liposomal formulation that comprises a liposome and a liquid carrier. In the liposomal formulation, the liposome comprises a hydrophobic lactone drug and has an intraliposomal metal ion concentration higher than the metal ion concentration of the liquid carrier. Also disclosed herein is a method for active loading of a hydrophobic lactone drug into a liposome. The method includes preparing a liposome in the presence of a metal salt solution, an acid form of a counterion of the metal salt being membrane permeable, such that the liposome preparation contains entrapped metal ion. The method further includes forming a liposome with high intraliposomal pH by separating extravesicular metal salt solution from the liposome by exposing the liposome to a metal salt-free solution, resulting in diffusion of the acid form of the counterion out of the liposome and formation of an intraliposomal pH higher than that of the metal salt-free solution. The method also includes exposing the liposome with high intraliposomal pH to an isoosmolal solution containing a hydrophobic lactone drug, the isoosmolal solution having a pH lower than the intraliposomal pH, such that the hydrophobic lactone drug accumulates in the liposome predominantly in its ring-opened form.
Multimodal sensory feedback from upper-limb prostheses can increase their function and usability. Here we show that intuitive thermal perceptions during cold-object grasping with a prosthesis can be restored in a phantom hand through targeted nerve stimulation via a wearable thin-film thermoelectric device with high cooling power density and speed. We found that specific regions of the residual limb, when thermally stimulated, elicited thermal sensations in the phantom hand that remained stable beyond 48 weeks. We also found stimulation sites that selectively elicited sensations of temperature, touch or both, depending on whether the stimulation was thermal or mechanical. In closed-loop functional tasks involving the identification of cold objects by amputees and by non-amputee participants, and compared with traditional bulk thermoelectric devices, the wearable thin-film device reliably elicited cooling sensations that were up to 8 times faster and up to 3 times greater in intensity while using half the energy and 1/600th the mass of active thermoelectric material. Wearable thin-film thermoelectric devices may allow for the non-invasive restoration of thermal perceptions during touch.
BACKGROUND: Sciatic nerve palsy is a rare but devastating complication following total hip arthroplasty (THA). While the use of the direct anterior approach is increasing, limited data exist regarding sciatic nerve palsy and surgical approach. The purpose of this study was to determine the factors and outcomes associated with sciatic nerve palsy (SNP) after THA.
METHODS: A retrospective analysis was performed at a single institution of 7 SNP that occurred in 4045 THA via direct anterior approach and 10 SNP in 8854 THA via posterior approach, being operated between 01 January 2017 and 12 December 2021. SNP patients were matched 1:5 to patients without SNP. Medical records were reviewed for demographics including age, gender, body mass index (BMI), comorbidities, and preoperative indication. Additional workup of SNP patients including advanced imaging and reoperation were documented. Recovery grades were assigned to all SNP patients at most recent clinical follow-up.
RESULTS: 5 of the SNP were complete and 12 partial. They occurred as frequently with the direct anterior (0.17%) and posterior approach (0.11%, p = 0.5). The presence of femur cables and reoperations were associated with SNP (p = 0.04 and p = 0.002, respecitvely). Age, gender, BMI, comorbidities, and surgical indication had no effect on SNP. 4 of the 17 affected patients had almost complete recovery at latest follow-up.
CONCLUSIONS: The incidence of SNP was similar in direct anterior and posterior approach. Surgeons should counsel patients regarding the risks of SNP regardless of the used approach.
Subjects will complete a short term training protocol while sitting \>11 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to anti-inflammatory preparation for topical use that has nimesulide as an active component. Nimesulide is mixed with the base in dispersed state. Preferable amount of nimesulide is 0.1-5 wt.-%, pH value is 4-8. Mixture of components taken among the group including hydrophilic polymer, white Vaseline, oily substance, nonionic surface-active agent, alkaline compound and absorption enhancer can be used as the base. Preparation can be made as emulsion or ointment. Method of preparing the preparation involves the gradual addition of nimesulide finely milled particles to the base and its dispersing in the base by stirring. Preferable mean diameter size of nimesulide particles is 0.01-75 mcm. Preparation does not stain skin and provides skin safety. EFFECT: enhanced absorbing capability of preparation. 14 cl, 2 tbl, 10 ex